Sanofi SA vs Western Alliance Bancorporation — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: Sanofi SA is far larger — about 11.9× Western Alliance Bancorporation's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | WAL | |
|---|---|---|
Market Cap | $104.83B | $8.84B |
Sector | Health | Financials |
52-Week High | $52.34 | $96.08 |
52-Week Low | $41.33 | $66.70 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | 2.07% |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →